About Cerexa
Cerexa is a company based in Alameda (United States) founded in 2005 was acquired by Forest Laboratories in December 2006. The company has 2,961 employees as of December 31, 2021. Cerexa operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Alameda, United States
- Employees 2961 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Abbvie Deutschland Gmbh & Co. Kg
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
2961
as on Dec 31, 2021
-
Acquired by
Forest Laboratories
(Dec 13, 2006)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cerexa
Detailed funding history for Cerexa
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Cerexa
Cerexa has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Forest Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical formulations are developed and marketed by Forest Laboratories.
|
Locked | Locked | Locked |
Investor details for Cerexa
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cerexa
Investment portfolio details for Cerexa
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cerexa
Detailed financials for Cerexa
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cerexa Comparisons
Peer comparison for Cerexa
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cerexa
Cerexa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
Detailed competitors of Cerexa
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cerexa
Complete news archive for Cerexa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cerexa
Cerexa was founded in 2005.
Cerexa is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
As of Dec 31, 2021, the latest employee count at Cerexa is 2,961.
Cerexa is focused on the development of hospital-based anti-infective therapies to infections that are resistant to antibiotics. Its product portfolio includes Ceftaroline Acetate, a hospital-based cephalosporin antibiotic that exhibits bactericidal activity against the strains of Gram- positive bacteria, including MRSA (methicillin-resistant Staphylococcus aureus); ME1036, a broad-spectrum parenteral carbapenem against both aerobic and anaerobic Gram-positive and Gram-negative bacteria, including common drug-resistant pathogens. On December 13, 2006 Forest Laboratories acquired Cerexa for a total of 480M.
Cerexa's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Cerexa has 1 investor. Key investors include Forest Laboratories.